Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants DOI Open Access
Laura Thümmler, Nadine Beckmann,

Caroline Sehl

et al.

Published: March 4, 2024

The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent challenge for the global system. In particular, individuals in developing countries with insufficient care need easily accessible, affordable effective treatments of COVID-19. Previous studies have demonstrated efficacy functional inhibitors acid sphingomyelinase (FIASMA) against infections various viruses, including early SARS-CoV-2. This work investigated whether fluoxetine sertraline, usually used as antidepressant molecules clinical practice, can inhibit replication former recently emerged vitro. Fluoxetine sertraline potently inhibited infection pseudotyped virus like particles D614G, alpha, delta, omicron BA.1 BA.5. These results highlight priority candidates large-scale phase 3 trials at different stages infections, either alone or combination other medications.

Language: Английский

Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants DOI Open Access
Laura Thümmler, Nadine Beckmann,

Caroline Sehl

et al.

Published: March 4, 2024

The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent challenge for the global system. In particular, individuals in developing countries with insufficient care need easily accessible, affordable effective treatments of COVID-19. Previous studies have demonstrated efficacy functional inhibitors acid sphingomyelinase (FIASMA) against infections various viruses, including early SARS-CoV-2. This work investigated whether fluoxetine sertraline, usually used as antidepressant molecules clinical practice, can inhibit replication former recently emerged vitro. Fluoxetine sertraline potently inhibited infection pseudotyped virus like particles D614G, alpha, delta, omicron BA.1 BA.5. These results highlight priority candidates large-scale phase 3 trials at different stages infections, either alone or combination other medications.

Language: Английский

Citations

1